Top Injectable Manufacturer in The Gambia – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 4 days ago
- 10 min read
Last Updated: September 3, 2026
TL;DR: The Gambia answers the question we always ask first — does the country keep a list of regulators it will rely on, and is India on it — with three lists at three layers, and India appears on none of them by name. The Medicines Control Agency's 2023 reliance policy names the EMA, the EU and EEA authorities, the MHRA, the US FDA, PMDA, Swissmedic, Health Canada, the TGA, WHO prequalification, AVAREF, ECOWAS and PIC/S, plus any authority the WHO has benchmarked at maturity level 3 or above; India's CDSCO holds that level for vaccines only, so a small-molecule injectable cannot use it. The 2025 reliance guideline works from the WHO-Listed Authorities list, and the June 2026 listing guideline names forty stringent-authority countries, from Australia to the United States, without India. The practical consequence is a full 180-day review rather than the 90-day abridged one, a local representative and a Gambia-resident pharmacovigilance person, and — uniquely for Indian exporters — a pre-shipment inspection and analysis certificate on every consignment. Out-of-pocket spending is a third of health expenditure and the public buyer is Central Medical Stores; on the MCA register roughly six in ten products are already made in India, which tells you the route works when it is walked properly.
Key Takeaways
Three lists, none with India. The MCA Reliance Policy of November 2023 lists recognised institutions by name and adds a general clause for authorities at WHO maturity level 3 or higher; CDSCO is benchmarked at level 3 for vaccines only. The June 2025 reliance guideline relies on the WHO-Listed Authorities list, AVAREF, ECOWAS/WAHO and WHO prequalification. The June 2026 listing guideline names forty stringent-authority countries; India is not among them. An Indian WHO-GMP injectable without an SRA authorisation or WHO prequalification takes the standard 180-day route.
The registration mechanics are written down and workable. Applications go in the MCA CTD format, with WAHO, WHO, EU or ICH CTD variants accepted, in English, with one hard copy of Module 1 and the rest on USB, three commercial-pack samples with batch certificates of analysis, a manufacturing licence and GMP certificate, and evidence that the product is registered and marketed in its country of origin. A non-resident holder must appoint a local representative registered in The Gambia and a pharmacovigilance person resident there. The authorisation lasts five years and may be renewed once for three.
India is singled out at the border. Since June 2023 every pharmaceutical consignment from India has needed a Clean Report of Inspection and Analysis issued through Quntrol Laboratories in Mumbai, with document review, physical inspection at loading, sampling and testing at an MCA-approved laboratory, a 90-day certificate validity and at least 60% shelf life remaining on arrival. We could not confirm how the regime is being enforced in 2026; a supplier should plan for it in full.
The commercial gate is the State and the programmes. Current health expenditure was about USD 26 per person and 2.9% of GDP in 2023, out-of-pocket payments were 33.8% of it, Central Medical Stores procures for the public facilities through the GPPA portal, and Global Fund grants for malaria, HIV and TB run to 2026 and 2027. The National Health Insurance Scheme has expanded from 13 to 69 contracted facilities; its medicines benefit has not been published in a form we could read.
Introduction: Why The Gambia Demands a Premium Injectable Manufacturer in The Gambia
Every market in this series opens with the same question: does the country publish a list of regulatory authorities whose decisions it will lean on, and is India's CDSCO among them? The Gambia is the first market where the honest answer is three lists at three layers, each of which we read. The first is the Medicines Control Agency's Reliance Policy, version 3 of 15 November 2023, whose appendix of recognised institutions names the European Medicines Agency, the national authorities of the EU and EEA states, the MHRA, the US FDA, Japan's PMDA, Swissmedic, Health Canada, Australia's TGA, WHO prequalification, AVAREF, the ECOWAS and WAHO harmonisation programme and PIC/S, and then adds a general clause for any national authority the WHO has benchmarked at maturity level 3 or above. That clause is the only door through which India could enter, and on the WHO's August 2026 list CDSCO holds maturity level 3 for vaccines only. For a sterile small-molecule injectable the door is closed.
The second layer is the Reliance Guideline MCA-GL-109, version 2 of 25 June 2025, with its annex of reference institutions: the WHO-Listed Authorities and the transitional list, AVAREF, the ECOWAS and WAHO regional mechanism and WHO prequalification, with partial reliance allowed for an active ingredient on the strength of a WHO certificate, a WHO prequalification confirmation or an EDQM certificate of suitability. The guideline also states that reliance on a decision which was itself based on reliance is not acceptable, which closes the indirect route through a third country. The third layer is the Listing Guideline MCA-GL-117 of 19 June 2026, made under the 2023 amendment to section 26 of the Medicines and Related Products Act, which names forty countries considered to have stringent regulatory authorities — Australia, the twenty-seven EU members, Iceland, Liechtenstein, Norway, Japan, Saudi Arabia, South Korea, Russia, Singapore, Switzerland, Turkey, the United Kingdom and the United States — and allows their approved products to be listed for import in ten working days without registration. India is not on it. What this means for a buyer is simple: a premium injectable manufacturer in The Gambia is one that registers the ordinary way, completely and on the first attempt.
What Sets a World-Class Injectable Manufacturer in The Gambia Apart
Start with the dossier, because the MCA has written it down more clearly than most agencies in the region. Registration Guideline MCA-GL-102, version 4, calls for the MCA common technical document and states that WAHO, WHO, EU and ICH CTD formats are accepted; a generic files Modules 1, 2 and 3 with the bioequivalence section of Module 5 where relevant, on application form MCA-F-112/01, with one hard copy of Module 1 and a complete electronic copy on USB. The language is English, with notarised translations of anything else. Three samples in commercial packs go in with signed batch certificates of analysis. The Module 1 checklist asks for evidence that the product is registered in its country of origin and a certificate from the competent authority there that it is marketed, with a WHO-format certificate of a pharmaceutical product listed among the certification documents as applicable; a manufacturing licence and a GMP certificate are mandatory for an imported product, and the agency reserves the right to inspect the site at a fee. The 2022 fees regulations, which we read from a scanned gazette and therefore quote with care, put registration of an imported medicine at USD 300, renewal at USD 300, and a GMP inspection outside West Africa at USD 7,000.
The clock is statutory and realistic. The agency acknowledges an application within two weeks, the standard review is 180 days and the abridged review for products with a stringent-authority authorisation or WHO prequalification is 90 days, with the clock stopping while queries are outstanding. A marketing authorisation is valid for five years and, under section 30 of the Act, may be renewed once for three years, after which a fresh application is required; the renewal must be filed at least 90 days before expiry and a late renewal is treated as a new application. Two structural requirements shape the commercial arrangement. A holder that is not resident in The Gambia must appoint a local representative that is a legal entity registered there, although the agency may accept a regional representative resident elsewhere in West Africa, and appointing one does not relieve the holder of legal responsibility. And the holder must have a qualified person for pharmacovigilance resident in The Gambia and file a summary of its pharmacovigilance system. We did not read the Act itself, which exists online only as page images, nor the 2020 regulations, so every requirement above is as the MCA's own guidelines quote it.
Quality Systems Behind Every Injectable Supplied to The Gambia
For a sterile injectable the evidence the MCA will look for is the evidence any inspector expects: media-fill records for the ISO Class 5 filling line, environmental monitoring trends, container-closure integrity, sterility and bacterial endotoxin testing by LAL, particulate matter, and HPLC or GC assay and impurity methods validated to ICH standards, with ICH Q1A stability data generated for the hot and humid zone rather than extrapolated. Because the GMP certificate is mandatory and India is not a recognised authority under the reliance policy, the certificate carries less weight than the file behind it, and a supplier should have the site master file and the last inspection report ready for the day the MCA exercises its right to visit.
The requirement that is unique to Indian suppliers deserves its own paragraph. Guidance MCA-G-113/04 of 15 June 2023, issued after the 2022 contaminated-syrup deaths, requires every pharmaceutical consignment from India to carry a Clean Report of Inspection and Analysis issued through Quntrol Laboratories in Mumbai. The exporter registers with the inspection body for a fee of INR 20,000, each shipment goes through a document check that includes the state licensing authority's product permission, the MCA registration certificate and a valid certificate of pharmaceutical product, a physical inspection at loading, and sampling and testing at an MCA-approved laboratory; injectables are analysed within about fifteen days, the certificate is valid for ninety days and the product must have at least sixty per cent of its shelf life remaining on arrival. The guidance is still listed on the agency's website; we could not establish how strictly it is applied in 2026 or what the per-shipment cost now is, and we will not guess. Plan for it in full and build the lead time into the supply contract.
Looking for a sterile injectable manufacturing partner? Talk to Farbe Firma about your market entry.
Why Farbe Firma is the Trusted Injectable Manufacturer in The Gambia for Global Buyers
Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than thirty countries. We build dossiers in CTD and ACTD format and we can present them in the MCA CTD layout the agency asks for, with the Module 1 certification pack — manufacturing licence, GMP certificate, WHO-format CPP, evidence of registration and marketing in India — assembled so that a 180-day review has nothing to send back. Our analytical package of HPLC, GC, LAL, Karl Fischer and ICH Q1A/Q1B stability is written to the standard a site inspection would test, and we are candid that no reliance shortcut is available to an Indian product in The Gambia without WHO prequalification. We also treat the pre-shipment regime as part of the delivery, not an obstacle to it.
The bilateral relationship is substantial and the pharmaceutical trade is established. India's Ministry of External Affairs brief records bilateral trade of USD 175.79 million in 2022–23, with Indian exports of USD 122.60 million, and lists drugs and pharmaceuticals among the major export items without ranking them; a joint commission agreement was signed in November 2021, and we found no health or pharmaceutical memorandum and no cooperation agreement between CDSCO and the MCA. UN Comtrade puts India-reported exports of pharmaceutical products to The Gambia at USD 8.66 million in 2022, USD 6.41 million in 2023, USD 9.46 million in 2024 and USD 8.81 million in 2025, while The Gambia reports imports from India of USD 3.62 million, USD 2.23 million and USD 3.07 million for 2022 to 2024; the two series differ by a factor of two to three and we give both rather than an average. The MCA's own register, updated in August 2026, carries about 2,500 products, and on a keyword count roughly six in ten are manufactured in India — a fact that says the route works, and that the competition on it is Indian.
Where the money is: The Gambia has 2.82 million people, gross national income per capita of USD 930 in 2025, current health expenditure of about USD 26 per person and 2.9% of GDP in 2023, and life expectancy of 66.1 years. Out-of-pocket payments were 33.8% of health expenditure in 2023, so the State and its partners are the larger buyer. The Directorate of National Pharmaceutical Services and Central Medical Stores procure and distribute for the public facilities, with tenders run under the Public Procurement Act 2022 on the GPPA portal, and the Global Fund's active grants — malaria to June 2027, HIV and TB to December 2026 — bring pooled procurement into the same warehouses. The National Health Insurance Scheme, created by the 2021 Act, expanded its contracted facilities from 13 to 69 in 2025 and is seeking mandatory contributions in 2026; its medicines benefit and any reimbursement list are not published in a form we could read. Tuberculosis incidence is 138 per 100,000, and the demand for sterile injectables is the general hospital formulary — antibiotics, anaesthetics, emergency and maternal-health medicines — rather than a single programme.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is India on The Gambia's list of recognised regulatory authorities?
Not by name on any of the three lists. The Reliance Policy of November 2023 names the EMA, EU and EEA authorities, MHRA, US FDA, PMDA, Swissmedic, Health Canada, TGA, WHO prequalification, AVAREF, ECOWAS/WAHO and PIC/S, plus any authority at WHO maturity level 3 or above; CDSCO holds that level for vaccines only. The June 2025 reliance guideline works from the WHO-Listed Authorities list, and the June 2026 listing guideline names forty stringent-authority countries without India. An Indian product therefore uses the standard 180-day registration route.
What does a Gambian registration application require?
Under Registration Guideline MCA-GL-102: an MCA-format CTD, or a WAHO, WHO, EU or ICH CTD, in English, with one hard copy of Module 1 and the full dossier on USB; three commercial-pack samples with batch certificates of analysis; a manufacturing licence and GMP certificate; evidence of registration and marketing in the country of origin with a WHO-format CPP as applicable; a local representative registered in The Gambia for a non-resident holder; and a Gambia-resident pharmacovigilance person. The 2022 fees regulations put registration of an imported medicine at USD 300.
How long does registration take and how long is it valid?
The MCA acknowledges within two weeks, reviews a standard application within 180 days and an abridged one within 90 days, with the clock stopping on queries. The authorisation is valid for five years and can be renewed once for three years, after which a fresh application is needed; renewal must be filed at least 90 days before expiry.
What is the pre-shipment inspection requirement for Indian medicines?
Since June 2023, guidance MCA-G-113/04 has required every pharmaceutical consignment from India to carry a Clean Report of Inspection and Analysis issued through Quntrol Laboratories in Mumbai, covering a document check, physical inspection at loading, and sampling and testing at an MCA-approved laboratory. Injectables are analysed in about fifteen days, the certificate is valid for ninety days and the product must arrive with at least 60% shelf life. We could not verify how it is enforced in 2026; plan for it in full.
How do we sell to the public sector in The Gambia?
Through Central Medical Stores and the Directorate of National Pharmaceutical Services, which procure for public facilities under the Public Procurement Act 2022 via the GPPA portal, and through the Global Fund programmes for malaria, HIV and TB whose grants run to 2026 and 2027. Registration with the MCA comes first, and a local importer holding MCA importer and warehouse licences is the practical partner. The National Health Insurance Scheme is expanding but its medicines benefit was not published in a form we could read.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments